Moderna (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced positive interim clinical data of mRNA-1273, its vaccine candidate against novel coronavirus (SARS-CoV-2), from the Phase 1 study led by the National Institute of Allergy and Infectious Diseases …
Three new alphacoronaviruses, three new betacoronaviruses, and one known alphacoronavirus previously identified in other southeast Asian countries were detected for the first time in bats in Myanmar. Studies in bats in China found over 400 coronaviruses. SARS-related viruses in these bat populations have the potential to go directly into human cells and do not need …
CanSino Biologics is starting phase II clinical trials for Ad5-nCoV, a COVID-19 vaccine candidate. Ad5-nCoV is a genetic engineered vaccine candidate with the replication-defective adenovirus type 5 as the vector to express SARS-CoV-2 spike protein, which intends to be used to prevent the disease caused by the novel coronavirus infection. In the phase 1 trial, …
Oxford University Professor Sarah Gilbert has been making and testing vaccines designed to induce T cell responses for ten years, chiefly using antigens from malaria and influenza. Based at the Jenner Institute, several of the vaccines developed in Professor Gilbert’s laboratory have progressed into Clinical Trials. Prof Ian Jones, Professor of Virology, University of Reading, …
Forfour years, MIGAL [The Galilee Research Institute] researchers has been developing a vaccine against infectious bronchitis virus (IBV), which causes a bronchial disease affecting poultry. The poultry coronavirus has high genetic similarity to the human COVID-19, and that it uses the same infection mechanism. This could be a lucky break for minor modification of the …
Moderna shipped the first samples of messenger RNA based coronavirus vaccine to the National Institute of Allergy and Infectious Disease in Bethesda Maryland. Human clinical trials should start in 6 weeks and the results could be available in July. The Moderna vaccine will need two doses but is considered to be safe. Moderna messenger RNA …
Doctors in Thailand combined the anti-flu drug oseltamivir with lopinavir and ritonavir, anti-virals used to treat HIV to cure a 71-year-old woman of coronavirus over a 48 hour period. Thailand’s Health ministry was awaiting research results to prove the findings. They have also stopped short of calling it a cure but it is a treatment. …
There has been 20 years of work on messenger RNA treatments against viruses. Technological advancements in RNA biology, chemistry, stability, and delivery systems have accelerated the development of fully synthetic mRNA vaccines. Molecular Therapy Journal (April 2019) reviewed mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases Vaccines – Enlisting the mRNA …
In 2003 it took 20 Months for the first experimental treatment for newly identified virus but in 2020 it appears it will take 3 months for the first treatments against the Wuhan Coronavirus. China has already published the genome sequence of the Wuhan Coronavirus and experimental vaccines should be in human testing by April, 2020. …
Bill Gates saw two positive trends in Alzheimer’s research in 2018. 1. Researchers focused on a new set of ideas about how to stop Alzheimer’s. The first generation of theories, which dominated the field for years, emphasized two proteins called amyloid and tau. These proteins cause plaques and tangles in the brain, clogging up and …
USC researchers have developed freeze-dried polio vaccine. It was freeze-dried into a powder, kept at room temperature for four weeks and then rehydrated, offered full protection against the polio virus when tested in mice. Polio is nearing complete eradication and had just 22 reported cases worldwide in 2017. The highly infectious disease, which causes lifelong …